Type 2 diabetes is routinely identified in clinical practice by tests that rely on a hyperglycemic index. However, people at risk for developing type 2 diabetes may not present with hyperglycemia. We identified several underlying risks for type 2 diabetes, insulin resistance, and associated co-morbidities, using a liquid chromatography mass spectrometry–based analysis of blood metabolites, in participants with normoglycemia and no clinical symptoms. Personalized lifestyle recommendations, including diet, exercise, and nutritional supplement recommendations, were conveyed to these participants by a web-based platform, and after 100 days of following their recommendations, these participants reported reductions in the health risks associated with type 2 diabetes and associated diseases. Our comprehensive metabolite-based assay can be used for type 2 diabetes risk stratification, and our personalized lifestyle recommendation system could be deployed as a preventative treatment option to improve health outcomes, reduce the incidence of chronic disease, and live healthier lives in an evidence-based way.
Get full access to this article
View all access options for this article.
References
1.
WishartDS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473–484. doi:10.1038/nrd.2016.32.
2.
AnwarMADaiDLWilson-McManusJ, et al.Multiplexed LC-ESI-MRM-MS-based assay for identification of coronary artery disease biomarkers in human plasma. Proteomics Clin Appl. 2019;13(4):e1700111. doi:10.1002/prca.201700111.
3.
International Diabetes Federation. Diabetes Atlas-Eighth Edition 2017. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. Available at: http://www.diabetesatlas.org. doi:10.1016/S0140-6736(16)31679-8.
4.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
5.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.
6.
BommerCHeesemannESagalovaV, et al.The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423–430. doi:10.1016/S2213-8587(17)30097-9.
7.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928. doi:10.2337/dci18-0007.
8.
KnowlerWCBarrett-ConnorEFowlerSE, et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin—NEJMoa012512. N Engl J Med. 2002;346(6):393–403. doi:10.1056/NEJMoa012512.
9.
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 2015;3(11):866–875. doi:10.1016/S2213-8587(15)00291-0.
10.
WilsonV. Reversing type 2 diabetes with lifestyle change. Nurs Times. 2015;111(12):17–19.
11.
RobertsCKBarnardRJ. Effects of exercise and diet on chronic disease. J Appl Physiol. 2005;98(1):3–30. doi:10.1152/japplphysiol.00852.2004.
12.
WilsonPWMeigsJBSullivanLFoxCSNathanDMD’AgostinoRBSr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068–1074.
13.
TiroshAShaiITekes-ManovaD, et al.Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353(14):1454–1462.
14.
ChoiS. HKimTHLimSParkKSJangHCChoNH. Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction. Diabetes Care. 2011;34(4):944–949. doi:10.2337/dc10-0644.
15.
TabakAGHerderCRathmanWBrunnerEJKivimakiM.Prediabetes : a high-risk state for developing diabetes. Lancet. 2014;379(9833):2279–2290. doi:10.1016/S0140-6736(12)60283-9.
16.
de VegtFDekkerJMJagerA, et al.Relation of impaired fasting and postload glucose with incident type 2 diabetes in a dutch population: the Hoorn Study. JAMA. 2001;285(16):2109–2113. doi:10.1001/jama.285.16.2109.
17.
AnjanaRM. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). Diabetes Care. 2015;38(8):1441–1448. doi:10.2337/dc14-2814.
18.
LeeJYMuratovSTarrideJEHolbrookAM. Managing high-cost healthcare users: the international search for effective evidence-supported strategies. J Am Geriatr Soc. 2018;66(5):1002–1008. doi:10.1111/jgs.15257.
19.
JohansenNJSaundersCM. Value-based care in the worldwide battle against cancer. Cureus. 2017;9(2):e1039. doi:10.7759/cureus.1039.
20.
PalumboR.Examining the impacts of health literacy on healthcare costs. An evidence synthesis. Health Serv Manage Res. 2017;30(4):197–212. doi:10.1177/0951484817733366.
21.
TsevatJ.MoriatesC. Value-based health care meets cost-effectiveness analysis. Ann Intern Med. 2018;169(5):329–332. doi:10.7326/M18-0342.
22.
NewgardCB. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311–326. doi:10.1016/j.cmet.2009.02.002.
23.
NewgardCB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15(5):606–614. doi:10.1016/j.cmet.2012.01.024.
24.
WangTJLarsonMGVasanRS, et al.Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–453. doi:10.1038/nm.2307.
25.
RheeEPChengSLarsonMG, et al.Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121(4):1402–1411. doi:10.1172/JCI44442.
26.
WangTJNgoDPsychogiosN, et al.2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123(10):4309–4317. doi:10.1172/JCI64801.
27.
FloegelAStefanNYuZ, et al.Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639–648. doi:10.2337/db12-0495.
28.
WalfordGAPornealaBCDaurizM, et al.Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care. 2014;37(9):2508–2514. doi:10.2337/dc14-0560.
29.
DroganDDunnWBLinW, et al.Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study. Clin Chem. 2015;61(3):487–497. doi:10.1373/clinchem.2014.228965.
30.
MerinoJLeongALiuCT, et al.Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose. Diabetologia. 2018;61(6):1315–1324.
31.
CullisP. The Personalized Medicine Revolution: How Diagnosing and Treating Disease Are About to Change Forever. Vancouver/Berkeley: Greystone Books; 2015.
32.
GrebeS.K.GSinghRJ. LC-MS/MS in the clinical laboratory—where to from here?Clin Biochem Rev. 2011;32(1):5–31.
33.
LehotayDCHallPLepageJEichhorstJCEtterMLGreenbergCR. LC-MS/MS progress in newborn screening. Clin Biochem. 2011;44(1):21–31. doi:10.1016/j.clinbiochem.2010.08.007.
34.
WishartDS. Advances in metabolite identification. Bioanalysis. 2011;3:1769–1782. doi:10.4155/bio.11.155.
35.
WishartDS. Computational strategies for metabolite identification in metabolomics. Bioanalysis. 2009;1(9):1579–1596. doi:10.4155/bio.09.138.
36.
DeshpandeADHarris-HayesMSchootmanM. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254–1264. doi:10.2522/ptj.20080020.
